Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer

Breast Cancer Research and Treatment

Volumn 127, Issue 2, 2011, Pages 511-520

  Rajan, Suja S ^a,b   Lyman, Gary H ^c   Carpenter, William R ^a   Stearns, Sally C ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; Colony stimulating factors; Neutropenia; Primary prophylaxis; Toxicities

Indexed keywords

ANTHRACYCLINE; J 1440; J 1441; J 2505; J 2820; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPENIA; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLONY-STIMULATING FACTORS; FEMALE; HUMANS; PHENOTYPE; SEER PROGRAM;

EID: 79958202739     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1216-1     Document Type: Article

References (51)

1. American Cancer Society (2009) Breast cancer facts and figures 2009-2010. ACS, Atlanta
2. Earle CC, Nattinger AB, Potosky AL et al (2002) Identifying cancer relapse using SEER-Medicare Data. Med Care 40(8 Suppl):IV-75-81
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1992 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women N Engl J Med 319 1681 1692
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1988 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1-15 71 85
7. B Fisher 1999 Highlights from recent national surgical adjuvant breast and bowel project studies in the treatment and prevention of breast cancer CA Cancer J Clin 49 159 177 10445015 10.3322/canjclin.49.3.159 1:STN:280: DyaK1MznsVSnsw%3D%3D (Pubitemid 29353929)
8. B Fisher C Redmond PS Legault, et al. 1990 Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16 J Clin Oncol 8 6 1005 1018 2189950 1:STN:280:DyaK3c3ntVyquw%3D%3D (Pubitemid 20200188)
9. GN Hortobagyi 1998 Treatment of breast cancer N Engl J Med 339 974 984 9753714 10.1056/NEJM199810013391407 1:CAS:528:DyaK1cXmslCitrY%3D (Pubitemid 28455101)
10. J Webster G Lyman 1996 Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study Cancer Control 3 6 519 523 10764511 (Pubitemid 27062011)
11. Perry MC, Yarbro JW (1984) Toxicity of chemotherapy. Gruene & Stratton, Orlando
12. M Shayne J Crawford DC Dale, et al. 2006 Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy Breast Cancer Res Treat 100 255 262 16705366 10.1007/s10549-006- 9254-4 (Pubitemid 44707919)
13. J Ziegler M Citron 2006 Dose-dense adjuvant chemotherapy for breast cancer Cancer Nurs 29 4 266 272 16871092 10.1097/00002820-200607000-00002 (Pubitemid 44181538)
14. EA Chrischilles KB Link SD Scott, et al. 2003 Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate grade non-Hodgkin's lymphoma Cancer Control 10 5 396 403 14581895 (Pubitemid 37296067)
15. A Eldar-Lissai LE Cosler E Culakova, et al. 2007 Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy Value Health 11 2 172 179 10.1111/j.1524-4733.2007.00242.x
16. N Kuderer D Dale J Crawford GH Lyman 2006 The morbidity, mortality and cost of febrile neutropenia in cancer patients Cancer 106 2258 2266 16575919 10.1002/cncr.21847 (Pubitemid 43673249)
17. GH Lyman CG Lyman RA Sanderson L Balducci 1993 Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy N Engl J Med 85 6 488 493 1:STN:280:DyaK3s7ovVSmtw%3D%3D (Pubitemid 23084095)
18. GH Lyman NM Kuderer J Greene 1998 The economics of febrile neutropenia: implications for the use of colony-stimulating factors Eur J Cancer 34 12 1857 1864 10023306 10.1016/S0959-8049(98)00222-6 1:STN:280:DyaK1M7kslertQ%3D%3D (Pubitemid 28535432)
19. Weycker D, Malin J, Glass A, Oster G (2007) Economic burden of chemotherapy-related febrile neutropenia. J Supp Oncol 5(4):Suppl 2:44-45
20. GH Lyman N Kuderer O Agboola, et al. 2003 Evidence-based use of colony-stimulating factors in elderly cancer patients Cancer Control 10 6 487 499 14652525 (Pubitemid 37493953)
21. NN Kuderer DC Dale J Crawford, et al. 2007 Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 21 3158 3167 17634496 10.1200/JCO.2006.08.8823 1:CAS:528: DC%2BD2sXptlGrtL4%3D (Pubitemid 47218066)
22. GH Lyman DC Dale J Crawford 2003 Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 4524 4531 14673039 10.1200/JCO.2003.05.002 (Pubitemid 46594022)
23. C Lenhart 2005 Relative dose intensity: improving cancer treatment and outcomes Oncol Nurs Forum 32 757 764 15990905 10.1188/05.ONF.757-764
24. Chrischilles EA, Rubenstein LM, Voelker MD, Wright et al (2003) Granulocyte colony-stimulating factor use during first course chemotherapy for non-Hodgkin's lymphoma: National SEER-Medicare Study. Session Type: Poster Session 929-I
25. XL Du DR Lairson E Begley, et al. 2005 Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort J Clin Oncol 23 34 8620 8628 16314624 10.1200/JCO.2005.02.6252 (Pubitemid 46211504)
26. S Chen-Hardee EA Chrischilles MD Voelker 2006 Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States) Cancer Causes Control 17 5 647 654 16633911 10.1007/s10552-005-0502-4 (Pubitemid 43668322)
27. EA Chrischilles DJ Delgado BS Stolshek 2002 Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma Cancer Control 9 3 203 211 12060818 (Pubitemid 34657282)
28. JO Armitage JF Potter 1984 Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age J Am Geriatr Soc 32 269 273 6368652 1:STN:280:DyaL2c7mtlWltw%3D%3D (Pubitemid 14135573)
29. H Gomez M Hidalgo L Casanova, et al. 1998 Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis J Clin Oncol 16 2065 2069 9626205 1:STN:280:DyaK1c3ovFCntw%3D%3D (Pubitemid 28265042)
30. M Shayne E Culakova MS Poniewierski, et al. 2007 Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy Cancer 110 7 1611 1620 17705197 10.1002/cncr.22939 (Pubitemid 47463077)
31. JN Timmer-Bonte EM Adang HJ Smit 2006 Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in patients with small-cell lung cancer J Clin Oncol 24 2991 2997 16682725 10.1200/JCO.2005.04.3281 1:CAS:528:DC%2BD28XnslKhsrg%3D (Pubitemid 46638931)
32. C Gridelli A Matti B Sandro B Giordano, et al. 2007 Role of colony stimulating factors (CSFs) in solid tumors: results of an expert panel Crit Rev Oncol Hematol 63 1 53 64 17368037 10.1016/j.critrevonc.2007.01.008 (Pubitemid 46810279)
33. T Berghmans M Paesmans JJ Lafitte, et al. 2002 Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis Support Care Cancer 10 181 188 11904782 10.1007/s00520-002-0396-6 1:STN:280:DC%2BD387nt1Cisg%3D%3D (Pubitemid 36056260)
34. O Clark GH Lyman AA Castro, et al. 2005 Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials J Clin Oncol 23 4198 4214 15961767 10.1200/JCO.2005.05.645 1:CAS:528:DC%2BD2MXmt1els7k%3D (Pubitemid 46211326)
35. LC Hartmann LK Tschetter TM Habermann, et al. 1997 Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia N Engl J Med 336 25 1776 1780 9187067 10.1056/NEJM199706193362502 1:CAS:528:DyaK2sXlt12itLo%3D (Pubitemid 27262173)
36. R García-Carbonero JI Mayordomo MV Tornamira, et al. 2001 Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial J Natl Cancer Inst 91 1 31 38 (Pubitemid 32060887)
37. GH Lyman NM Kuderer 2004 The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia Crit Rev Oncol Hematol 50 129 146 15157662 10.1016/j.critrevonc.2004.01.001 1:STN:280: DC%2BD2c3lvFCisQ%3D%3D (Pubitemid 38638740)
38. Package insert. Neupogen (Filgrastim). Amgen. www.neupogen.com. Accessed 26 March 2009
39. D Weycker J Hackett JS Edelsberg, et al. 2006 Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40 402 407 16492793 10.1345/aph.1G516 1:CAS:528: DC%2BD28XjsFagsr4%3D
40. Weycker D, Hackett J, Edelsberg JS et al (2004) Duration of G-CSF therapy and risk of hospitalization for neutropenia or infection. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S) (July 15 Supplement): 6731
41. SD Scott EA Chrischilles BK Link, et al. 2003 Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy J Manag Care Pharm 9 Suppl 2 15 21 14613340
42. Warren JL, Klabunde CN, Schrag Deborah et al (2002) Overview of the SEER-Medicare Data: content, research applications, and generalizability to the United States Elderly Population. Med Care 40(8): IV-3-IV-18
43. CL Shapiro A Recht 2001 Side effects of adjuvant treatment of breast cancer N Engl J Med 344 26 1997 2008 11430330 10.1056/NEJM200106283442607 1:CAS:528:DC%2BD3MXltFers78%3D (Pubitemid 32568155)
44. J Crawford H Kreisman H Garewal, et al. 1997 The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy Ann Oncol 8 1117 1124 9426331 10.1023/A:1008271804151 1:STN:280:DyaK1c%2FoslOisw%3D%3D (Pubitemid 27521219)
45. GH Lyman 2003 Risk assessment in oncology clinical practice: from risk factors to risk models Oncology 17 Suppl 11 8 13 14682113
46. Lyman GH, Kuderer NM (2004) Economics of hematopoietic growth factors. In: Morstyn G, Foote M, Lieschke GJ (eds) Hematopoietic growth factors in oncology: basic science and clinical therapeutics. Humana Press Inc., Totowa, pp 409-443
47. Levinson DR (2009) Medicare part B chemotherapy administration: payment and policy. Department of Health and Human Services, Washington
48. M Olsen 2006 Medicare reimbursement issues in supportive care Cancer Ther Supportive Care 4 1 5 8
49. Amgen (2001) Guide to coverage and reimbursement for Neupogen vial and Neupogen singleject prefilled syringe: reimbursement information for Neupogen. Amgen Inc., Thousand Oaks
50. TJ Smith J Khatcheressian GH Lyman, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 19 3187 3205 16682719 10.1200/JCO.2006.06. 4451 1:CAS:528:DC%2BD28XnslKhsLo%3D (Pubitemid 46638957)
51. Rolston KV (2004) The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 39(Suppl 1):S44-S48 (Pubitemid 38971475)